Parminder Singh, MD
In bladder cancer, combination strategies, particularly the combination of immunotherapy and chemotherapy, are under investigation. Chemotherapy, says Parminder Singh, MD, is going to make a comeback to improve treatment efficacy.
State of the Science Summit™ on Genitourinary Cancers, Singh, hematologist/ oncologist, Mayo Clinic, discussed the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive disease.
OncLive®: What is the state of immunotherapy in bladder cancer?
: Immune therapy is efficacious for patients with bladder cancer, but there are potential toxicities and interactions with other medications to be aware of.
KEYNOTE-045 showed that pembrolizumab (Keytruda) sustained its improvement in overall survival compared with chemotherapy. Is the future headed toward combination approaches or continued use of single-agent therapy?
We already have 5 FDA-approved agents based on immune checkpoint pathways. They all have activity as single agents, but we know the activity of these agents is limited to a small group of patients. We want to expand those results to other patients who progress.
... to read the full story